Nicola Zetola

Nicola Zetola


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
NZNicola Zetola
Nicola Zetola
SSSanghyuk S. Shin
Sanghyuk S. Shin
KTKefentse A. Tumedi
Kefentse A. Tumedi
KMKeletso Moeti
Keletso Moeti
RNRonald Thulani Ncube
Ronald Thulani Ncube
CMChawangwa Modongo
Chawangwa Modongo
The Xpert MTB/RIF (Xpert) assay is becoming a principal screening tool for diagnosing rifampin-resistant Mycobacterium tuberculosis complex (MTBC) infection. However, little is known about the performance of the Xpert assay in infections with both drug-sensitive and drug-resistant strains (mixed MTBC infections). We assessed the performance of the Xpert assay for detecting rifampin resistance using phenotypic drug sensitivity testing (DST) as the reference standard in 370 patients with microbiologically proven pulmonary tuberculosis. Mixed MTBC infections were identified genetically through 24-locus mycobacterial interspersed repetitive-unit–variable-number tandem-repeat (MIRU-VNTR) analysis. Logistic regression was used to identify the factors associated with poor (defined as treatment failure, default, and death from any cause) or good (defined as cure or successful treatment completion) clinical outcomes. The analytic sensitivity of the Xpert assay for detecting rifampin resistance was assessed in vitro by testing cultures containing different ratios of drug-sensitive and drug-resistant organisms. Rifampin resistance was detected by the Xpert assay in 52 (14.1%) and by phenotypic DST in 55 (14.9%) patients. Mixed MTBC infections were identified in 37 (10.0%) patients. The Xpert assay was 92.7% (95% confidence interval [CI], 82.4% to 97.9%) sensitive for detecting rifampin resistance and 99.7% (95% CI, 98.3% to 99.9%) specific. When restricted to patients with mixed MTBC infections, Xpert sensitivity was 80.0% (95% CI, 56.3 to 94.3%). False-negative Xpert results (adjusted odds ratio [aOR], 6.6; 95% CI,1.2 to 48.2) and mixed MTBC infections (aOR, 6.5; 95% CI, 2.1 to 20.5) were strongly associated with poor clinical outcome. The Xpert assay failed to detect rifampin resistance in vitro when <90% of the organisms in the sample were rifampin resistant. Our study indicates that the Xpert assay has an increased false-negative rate for detecting rifampin resistance with mixed MTBC infections. In hyperendemic settings where mixed infections are common, the Xpert results might need further confirmation.

14 January 2009 in BMC Public Health
Verified
Journal Article
Open access
PDF file
NZNicola Zetola
Nicola Zetola
KBKyle Bernstein
Kyle Bernstein
KAKatherine Ahrens
Katherine Ahrens
JMJulia L Marcus
Julia L Marcus
SPSusan Philip
Susan Philip
JKJeffrey D Klausner
Jeffrey D Klausner
Background: Linkage to care after HIV diagnosis is associated with both clinical and public health benefits. However, ensuring and monitoring linkage to care by public health departments has proved to be a difficult task. Here, we report the usefulness of routine monitoring of CD4 T cell counts and plasma HIV viral load as measures of entry into care after HIV diagnosis. Methods: Since July 1, 2006, the San Francisco Department of Public Health (SFDPH) incorporated monitoring initial primary care visit into standard HIV public health investigation for newly diagnosed HIV-infected patients in select clinics. Entry into care was defined as having at least one visit to a primary HIV care provider after the initial diagnosis of HIV infection. Investigators collected reports from patients, medical providers, laboratories and reviewed medical records to determine the date of the initial health care visit after HIV diagnosis. We identified factors associated with increased likelihood of entering care after HIV diagnosis. Results: One -hundred and sixty new HIV-infected cases were diagnosed between July 1, 2006 and June 30, 2007. Routine surveillance methods found that 101 of those cases entered HIV medical care and monitoring of CD4 T cell counts and plasma HIV viral load confirmed entry to care of 25 more cases, representing a 25% increase over routine data collection methods. We found that being interviewed by a public health investigator was associated with higher odds of entry into care after HIV diagnosis (OR 18.86 [1.83–194.80], p = .001) compared to cases not interviewed. Also, HIV diagnosis at the San Francisco county hospital versus diagnosis at the county municipal STD clinic was associated with higher odds of entry into care (OR 101.71 [5.29–1952.05], p < .001). Conclusion: The time from HIV diagnosis to initial CD4 T cell count, CD4 T cell value and HIV viral load testing may be appropriate surveillance measures for evaluating entry into care, as well as performance outcomes for local public health departments' HIV testing programs. Case investigation performed by the public health department or case management by clinic staff was associated with increased and shorter time to entry into HIV medical care.

1 November 2012 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
NZNicola Zetola
Nicola Zetola
CMC. Modongo
C. Modongo
EKE. C. Kip
E. C. Kip
RGR. Gross
R. Gross
GBG. P. Bisson
G. P. Bisson
RCR. G. Collman
R. G. Collman
BACKGROUND: Data on alcohol abuse as a risk factor for the development of multidrug-resistant tuberculosis (MDR-TB) are scarce. OBJECTIVE: To describe the patterns of alcohol use in MDR-TB patients and to determine whether alcohol use is associated with the development of MDR-TB in Botswana. METHODS: We compared the level of alcohol use among MDR-TB patients against three control groups: 1) non-MDR-TB patients, 2) human immunodeficiency virus (HIV) infected patients without a history of TB, and 3) the general population. Alcohol use and abuse was measured with the Alcohol Use Disorders Identification Test 10 (AUDIT) questionnaire. RESULTS: Of a total national population of 164 MDR-TB cases, 114 (70%) were interviewed. MDR-TB cases had a lifetime prevalence of alcohol use of 35.1%, which was lower than that of all control groups (P < 0.001). MDR-TB cases had higher 1-month prevalence of alcohol dependence symptoms and a lower 1-year period prevalence of alcohol dependence symptoms (P < 0.01 and P = 0.01 respectively). Among patients with TB, alcohol abuse was found to be a risk factor for the development of MDR-TB. CONCLUSION: MDR-TB patients in Botswana have high rates of alcohol use and abuse. Among TB patients, alcohol abuse is associated with the diagnosis of MDR-TB, and could be an important modifiable factor.

28 July 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SSSanghyuk S. Shin
Sanghyuk S. Shin
CMChawangwa Modongo
Chawangwa Modongo
RNRonald Thulani Ncube
Ronald Thulani Ncube
ESEnoch Sepako
Enoch Sepako
JKJeffrey D. Klausner
Jeffrey D. Klausner
NZNicola Zetola
Nicola Zetola
We examined factors associated with mixed-strain Mycobacterium tuberculosis infections among patients at high risk for drug-resistant tuberculosis in Botswana. Thirty-seven (10.0%) of 370 patients with tuberculosis had mixed M. tuberculosis infections, based on 24-locus mycobacterial interspersed repetitive unit–variable number of tandem repeats genotyping. In log-binomial regression analysis, age <37 years (adjusted prevalence ratio [PR], 1.92; 95% confidence interval [CI], 1.01–3.57) and prior tuberculosis treatment (adjusted PR, 2.31; 95% CI, 1.09–4.89) were associated with mixed M. tuberculosis infections. Among human immunodeficiency virus–infected patients, prior tuberculosis treatment (adjusted PR, 2.11; 95% CI, 1.04–4.31) and CD4+ T-cell count of <100 cells/μl (adjusted PR, 10.18; 95% CI, 2.48–41.71) were associated with mixed M. tuberculosis infections. Clinical suspicion of mixed M. tuberculosis infections should be high for patients with advanced immunosuppression and a prior history of tuberculosis treatment.

22 July 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NZNicola Zetola
Nicola Zetola
NMNenad Macesic
Nenad Macesic
CMChawangwa Modongo
Chawangwa Modongo
SSSanghuk Shin
Sanghuk Shin
RNRonald Thulani Ncube
Ronald Thulani Ncube
RCRonald G Collman
Ronald G Collman
Nosocomial transmission of pulmonary tuberculosis (PTB) is a problem in resource-limited settings. However, the degree of TB exposure and the intermediate- and long-term morbidity and mortality of hospital-associated TB is unclear. In this study we determined: 1) the nature, patterns and intensity of TB exposure occurring in the context of current TB cohorting practices in medical centre with a high prevalence of TB and HIV; 2) the one-year TB incidence after discharge; and 3) one-year TB-related mortality after hospital discharge.

1 November 2012 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Open access
CMChawangwa Modongo
Chawangwa Modongo
NZNicola Zetola
Nicola Zetola